TheStreet upgraded shares of Halyard Health (NYSE:HYH) from a c+ rating to a b rating in a research note issued to investors on Monday morning.

Other research analysts have also recently issued reports about the stock. BidaskClub raised shares of Halyard Health from a hold rating to a buy rating in a research report on Saturday, August 19th. Stifel Nicolaus reissued a buy rating and set a $45.00 price target on shares of Halyard Health in a research report on Thursday, September 21st. Zacks Investment Research cut shares of Halyard Health from a buy rating to a sell rating in a research report on Wednesday, October 4th. KeyCorp reissued a hold rating on shares of Halyard Health in a research report on Tuesday, October 17th. Finally, ValuEngine raised shares of Halyard Health from a hold rating to a buy rating in a research report on Saturday, November 4th. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The company presently has a consensus rating of Buy and a consensus target price of $46.25.

Shares of Halyard Health (NYSE HYH) opened at $47.12 on Monday. Halyard Health has a 12-month low of $35.24 and a 12-month high of $50.99. The company has a debt-to-equity ratio of 0.49, a current ratio of 2.13 and a quick ratio of 1.19. The company has a market cap of $2,210.00, a PE ratio of 22.68, a PEG ratio of 2.56 and a beta of 1.77.

Halyard Health (NYSE:HYH) last posted its earnings results on Wednesday, November 1st. The medical instruments supplier reported $0.60 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.47 by $0.13. Halyard Health had a net margin of 3.52% and a return on equity of 8.65%. The firm had revenue of $401.40 million during the quarter, compared to analysts’ expectations of $394.54 million. During the same period last year, the company posted $0.48 EPS. The company’s quarterly revenue was up 1.0% compared to the same quarter last year. research analysts predict that Halyard Health will post 2.08 earnings per share for the current year.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. AXA lifted its position in Halyard Health by 2.7% during the 3rd quarter. AXA now owns 142,800 shares of the medical instruments supplier’s stock valued at $6,430,000 after acquiring an additional 3,700 shares during the period. Public Employees Retirement System of Ohio lifted its position in Halyard Health by 374.0% during the 3rd quarter. Public Employees Retirement System of Ohio now owns 25,328 shares of the medical instruments supplier’s stock valued at $1,141,000 after acquiring an additional 19,984 shares during the period. Pura Vida Investments LLC purchased a new position in Halyard Health during the 3rd quarter valued at about $3,377,000. Cubist Systematic Strategies LLC raised its holdings in Halyard Health by 1,913.0% in the third quarter. Cubist Systematic Strategies LLC now owns 18,801 shares of the medical instruments supplier’s stock worth $847,000 after buying an additional 17,867 shares during the last quarter. Finally, Patten Group Inc. raised its holdings in Halyard Health by 1,342.6% in the third quarter. Patten Group Inc. now owns 281,112 shares of the medical instruments supplier’s stock worth $877,000 after buying an additional 261,626 shares during the last quarter. 90.31% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “Halyard Health (HYH) Upgraded by TheStreet to “B”” was posted by Watch List News and is owned by of Watch List News. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright & trademark legislation. The correct version of this report can be read at https://www.watchlistnews.com/halyard-health-hyh-upgraded-by-thestreet-to-b/1750578.html.

About Halyard Health

Halyard Health, Inc is a medical technology company. The Company operates through two segments: Medical Devices and Surgical and Infection Prevention (S&IP). The Medical Devices segment provides a portfolio of product offerings focused on pain management, respiratory and digestive health. The S&IP segment provides healthcare supplies and solutions that target the prevention of healthcare-associated infections.

Analyst Recommendations for Halyard Health (NYSE:HYH)

Receive News & Ratings for Halyard Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halyard Health Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.